TICKERNERD
Menu
ERASERASHealthcare · Biotechnology

ERAS Stock Forecast: Erasca, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$16
−0.94% on the day

The 9 Wall Street analysts covering Erasca, Inc. hold a median 12-month price target of $22 — +38.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$5.6B
Ticker Nerd rank
55 / 100
Median analyst target
$22
Analysts covering
9
Revenue$0.0
Operating income−$47.6M
Net income−$44.1M
Free cash flow−$27.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.3%
1M
−13.3%
YTD
+326.9%
1Y
+886.3%
From 52W high
−29.3%
From 52W low
+917.9%
$2
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ERAS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Erasca, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
90
Accruals
85
Momentum
85
Quality
55
Issuance
50
Volatility
35
Revisions
33
Growth
28
Size
22

Value (90): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (28): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ERAS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ERAS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30Oct 25Jan 26Apr 26Jul 26ERASHigh $33Median $22Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
7 Buy2 Hold0 Sell
Low $20Median $22High $33

The green dot is the last close — the median target sits +38.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Aug 2026B of A SecuritiesMaintainsNeutral$18 → $20
13 Aug 2026GuggenheimMaintainsBuy$20 → $21
12 Aug 2026HC Wainwright & Co.MaintainsBuy$18 → $22
20 July 2026Morgan StanleyMaintainsEqual-Weight$12 → $21
20 July 2026Morgan StanleyMaintainsEqual-Weight—
14 July 2026B of A SecuritiesMaintainsNeutral$16 → $18
14 July 2026B of A SecuritiesMaintainsNeutral—
4 June 2026B of A SecuritiesUpgradeNeutral$9.00 → $16
4 June 2026B of A SecuritiesUpgradeNeutral—
12 May 2026MizuhoMaintainsOutperform—
27 Apr 2026StifelMaintainsBuy—
18 Mar 2026JP MorganMaintainsOverweight—
16 Mar 2026GuggenheimMaintainsBuy—
13 Mar 2026HC Wainwright & Co.MaintainsBuy—
13 Mar 2026MizuhoMaintainsOutperform—
13 Mar 2026Piper SandlerMaintainsOverweight—
6 Mar 2026Clear StreetMaintainsBuy—
26 Jan 2026HC Wainwright & Co.MaintainsBuy—
16 Jan 2026Piper SandlerMaintainsOverweight—
13 Jan 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ERAS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ERAS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Erasca, Inc. returned +886.3% against +17.5% for the S&P 500, dividends included.

ERAS vs S&P 500, last 12 monthsTotal return, rebased to 100
05001,0001,500Oct 25Jan 26Apr 26Jul 26ERASS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ERAS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
6
Fundamentals

Erasca, Inc. (ERAS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−36.1×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
13.7×

Cheaper than 7% of US stocks

EV / EBITDA
−36.1×

Cheaper than 93% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−78.2%

Higher than 16% of US stocks

Return on assets
−21.4%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Erasca, Inc. (ERAS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Erasca, Inc. has a market value of $5.6B and an enterprise value of $5.3B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$287.2M.

  • Diluted earnings per share, trailing twelve months: $−0.95.

  • Free cash flow in the twelve months to 30 June 2026: −$252.1M.

  • Shares outstanding: 312.6M.

  • Trailing P/E: −36.1×; forward P/E: −25.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Erasca, Inc. employs 103 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

ERAS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ERASErasca, Inc.$5.6B
55
PTCTPTC Therapeutics, Inc.$5.5B
65
XENEXenon Pharmaceuticals, Inc.$5.6B
50
LGNDLigand Pharmaceuticals, Inc.$5.6B
73
COGTCogent Biosciences, Inc.$5.7B
35
DNTHDianthus Therapeutics, Inc.$5.8B
61
DFTXDefinium Therapeutics, Inc.$5.0B
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Erasca, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ERAS news & analysis

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

GlobeNewsWire · 10 Sept 2026positive

Erasca announced it will present at the 38th EORTC-NCI-AACR Symposium in Barcelona (November 18-20), including an oral presentation of updated monotherapy clinical data from the ongoing Phase 1 AURORAS-1 trial of ERAS-0015, and a poster presentation of nonclinical combination data for ERAS-0015 and ERAS-4001 in KRAS G12X-driven models.

Why it matters — The presentations offer ERAS watchers a chance to see updated clinical data on ERAS-0015 with additional patients and longer follow-up, plus early combination data for the ERAS-4001 program.

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewsWire · 8 Sept 2026neutral

Erasca, Inc. announced that it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, to be held at the New York Marriott Marquis in New York, NY. The clinical-stage precision oncology company focuses on developing therapies for RAS/MAPK pathway-driven cancers.

Why it matters — Participation in a major investment conference gives Erasca a platform to present its pipeline to the financial community.

Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims

GlobeNewsWire · 2 Sept 2026negative

Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Erasca, Inc. against certain of its officers and directors for alleged breaches of fiduciary duty. The firm is encouraging affected shareholders to contact it regarding these potential claims.

Why it matters — This news signals possible legal scrutiny of Erasca's leadership over alleged fiduciary breaches, which long-term ERAS shareholders would want to monitor.

ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

GlobeNewsWire · 2 Sept 2026negative

Bernstein Liebhard LLP announced it is investigating potential breaches of fiduciary duty by certain directors and officers of Erasca, Inc. The law firm, which specializes in investor rights, said it is opening this investigation into the company.

Why it matters — ERAS watchers would care because a shareholder investigation into alleged fiduciary breaches by company leadership could signal legal and governance concerns.

ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

Newsfile Corp · 26 Aug 2026negative

Bernstein Liebhard LLP announced it is investigating potential breaches of fiduciary duty by certain directors and officers of Erasca, Inc. The law firm is examining whether the company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.

Why it matters — A shareholder investigation into potential breaches of fiduciary duty signals possible governance concerns that ERAS watchers would want to monitor.

FAQ

Frequently asked questions about ERAS stock

What is the ERAS stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Erasca, Inc. have a median 12-month price target of $22, with estimates ranging from $20 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ERAS stock a buy right now?

Of the 9 analysts covering Erasca, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Erasca, Inc. 55 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ERAS?

As at 12 Sept 2026, Erasca, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (90 of 100).

Will ERAS stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +38.5% from the last close, and Ticker Nerd's factor model ranks Erasca, Inc. 55 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ERAS stock forecast for 2030?

No analyst covering Erasca, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ERAS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $33 over the next 12 months.

How has ERAS stock performed over the past year?

Erasca, Inc. returned +886.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Erasca, Inc. do?

Erasca Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK signaling pathway.

What is the latest news on ERAS?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium". Erasca announced it will present at the 38th EORTC-NCI-AACR Symposium in Barcelona (November 18-20), including an oral presentation of updated monotherapy clinical data from the ongoing Phase 1 AURORAS-1 trial of ERAS-0015, and a poster presentation of nonclinical combination data for ERAS-0015 and ERAS-4001 in KRAS G12X-driven models.

Company

About Erasca, Inc.

Erasca Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK signaling pathway. The company’s current portfolio centers on targeted drug candidates designed to address difficult-to-treat solid tumors through biomarker-guided approaches. Its development programs span multiple mechanisms, including agents that act on key nodes within the RAS/MAPK pathway and therapies intended to overcome resistance pathways in cancer cells. Erasca’s work is concentrated on precision medicine in oncology, with an emphasis on selecting patient populations most likely to benefit from its investigational treatments. Based in San Diego, California, Erasca plays a role in the biotechnology market as a research-driven company advancing experimental cancer therapies through clinical development and collaborative studies.

CEO Dr. Jonathan E. Lim M.D. · 103 employees · United States · https://www.erasca.com